JP2004528810A - 癌組織でディファレンシャルに発現される核酸配列 - Google Patents

癌組織でディファレンシャルに発現される核酸配列 Download PDF

Info

Publication number
JP2004528810A
JP2004528810A JP2002532655A JP2002532655A JP2004528810A JP 2004528810 A JP2004528810 A JP 2004528810A JP 2002532655 A JP2002532655 A JP 2002532655A JP 2002532655 A JP2002532655 A JP 2002532655A JP 2004528810 A JP2004528810 A JP 2004528810A
Authority
JP
Japan
Prior art keywords
nucleic acid
nos
seq
cell
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002532655A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004528810A5 (cg-RX-API-DMAC7.html
Inventor
クリストファー バージェス，
ジョン， エイチ． アスツル，
エディ， サード キャロル，
セオドール， ジェー． カチノ，
プーアニーマ ドウィヴェディ，
ギャリー， エイ． モリノ，
アランサッチ チアゲイリンガム，
マルシア， イー． リーヴァイス，
Original Assignee
バイエル コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイエル コーポレーション filed Critical バイエル コーポレーション
Publication of JP2004528810A publication Critical patent/JP2004528810A/ja
Publication of JP2004528810A5 publication Critical patent/JP2004528810A5/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G01N33/575—
    • G01N33/57535—
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2002532655A 2000-10-02 2001-10-02 癌組織でディファレンシャルに発現される核酸配列 Pending JP2004528810A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23727100P 2000-10-02 2000-10-02
PCT/US2001/030732 WO2002029086A2 (en) 2000-10-02 2001-10-02 Nucleic acid sequences differentially expressed in cancer tissue

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2007150552A Division JP2007289196A (ja) 2000-10-02 2007-06-06 癌組織でディファレンシャルに発現される核酸配列

Publications (2)

Publication Number Publication Date
JP2004528810A true JP2004528810A (ja) 2004-09-24
JP2004528810A5 JP2004528810A5 (cg-RX-API-DMAC7.html) 2007-02-15

Family

ID=22893028

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002532655A Pending JP2004528810A (ja) 2000-10-02 2001-10-02 癌組織でディファレンシャルに発現される核酸配列
JP2007150552A Pending JP2007289196A (ja) 2000-10-02 2007-06-06 癌組織でディファレンシャルに発現される核酸配列

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2007150552A Pending JP2007289196A (ja) 2000-10-02 2007-06-06 癌組織でディファレンシャルに発現される核酸配列

Country Status (5)

Country Link
US (2) US20040110668A1 (cg-RX-API-DMAC7.html)
EP (1) EP1330543A4 (cg-RX-API-DMAC7.html)
JP (2) JP2004528810A (cg-RX-API-DMAC7.html)
AU (1) AU2001294943A1 (cg-RX-API-DMAC7.html)
WO (1) WO2002029086A2 (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7258973B2 (en) 1998-08-31 2007-08-21 Mayo Foundation For Medical Education & Research Method for detecting a differentially expressed sequence
EP1686174A1 (en) * 2000-06-02 2006-08-02 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7736654B2 (en) 2001-04-10 2010-06-15 Agensys, Inc. Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
WO2003025214A1 (en) 2001-09-14 2003-03-27 Medimolecular Pty. Ltd. Nucleic acid markers for use in determining predisposition to neoplasm and/or adenoma
US7449548B2 (en) 2001-12-07 2008-11-11 Agensys, Inc. Nucleic acid and corresponding protein entitled 193P1E1B useful in treatment and detection of cancer
EP2269628A3 (en) 2002-05-29 2011-04-20 DeveloGen Aktiengesellschaft Pancreas-specific proteins
WO2004005458A2 (en) * 2002-06-13 2004-01-15 Regulome Corporation Functional sites
US20040081653A1 (en) 2002-08-16 2004-04-29 Raitano Arthur B. Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer
US7393950B2 (en) * 2002-08-29 2008-07-01 Hong Kong University Of Science & Technology Antisense oligonucleotides targeted to human CDC45
CA2518101A1 (en) * 2003-03-03 2005-06-09 Genentech, Inc. Compositions and methods for the treatment of systemic lupus erythematosis
WO2005017102A2 (en) * 2003-05-30 2005-02-24 Diadexus, Inc. Compositions, splice variants and methods relating to ovarian specific nucleic acids and proteins
DE10332854A1 (de) * 2003-07-18 2005-02-17 Universitätsklinikum der Charité der Humboldt-Universität zu Berlin Verwendung des neu-identifizierten humanen Gens 7a5/Prognostin für Tumordiagnostik und Tumortherapie
JP4643450B2 (ja) 2003-08-08 2011-03-02 株式会社ペルセウスプロテオミクス 癌高発現遺伝子
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
US20060134653A1 (en) * 2004-07-28 2006-06-22 Bayer Healthcare Llc Differential expression of genes in microsatellite instability
US8535914B2 (en) * 2005-01-21 2013-09-17 Canon Kabushiki Kaisha Probe, probe set and information acquisition method using the same
FR2919062B1 (fr) * 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de l'aminoacylase 1 pour le diagnostic in vitro du cancer colorectal.
FR2919060B1 (fr) * 2007-07-19 2012-11-30 Biomerieux Sa Procede de dosage de l'ezrine pour le diagnostic in vitro du cancer colorectal.
FR2919061B1 (fr) * 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de la plastine-i pour le diagnostic in vitro du cancer colorectal.
FR2919064B1 (fr) * 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de l'apolipoproteine all pour le diagnostic in vitro du cancer colorectal
WO2009019368A2 (fr) * 2007-07-19 2009-02-12 bioMérieux Procede de dosage de la liver fatty acid-binding protein, de l'ace et du ca19-9 pour le diagnostic in vitro du cancer colorectal
FR2919063B1 (fr) * 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage du leucocyte elastase inhibitor pour le diagnostic in vitro du cancer colorectal.
FR2919065B1 (fr) 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de l'apolipoproteine ai pour le diagnostic in vitro du cancer colorectal
FR2933773B1 (fr) * 2008-07-10 2013-02-15 Biomerieux Sa Procede de dosage de la proteine disulfide isomerase pour le diagnostic in vitro du cancer colorectal
WO2010135786A1 (en) * 2009-05-29 2010-12-02 Clinical Genomics Pty. Ltd. A method for diagnosing neoplasms and molecules for use therein
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
AU2015200751B2 (en) * 2010-03-19 2016-11-10 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors including gastrointestinal and gastric cancer
WO2018132358A1 (en) * 2017-01-10 2018-07-19 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
JP6702932B2 (ja) * 2017-12-27 2020-06-03 富士フイルム株式会社 細胞撮像制御装置および方法並びにプログラム

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2135194A1 (en) * 1992-05-22 1993-12-09 Charles L. Bevins Gastrointestinal defensins, cdna sequences and method for the production and use thereof
US5861494A (en) * 1995-06-06 1999-01-19 Human Genome Sciences, Inc. Colon specific gene and protein
US6171816B1 (en) * 1996-08-23 2001-01-09 Human Genome Sciences, Inc. Human XAG-1 polynucleotides and polypeptides
US5837841A (en) * 1996-10-11 1998-11-17 Incyte Pharmaceuticals, Inc. Human Reg protein
WO1998041627A1 (en) * 1997-03-19 1998-09-24 Zymogenetics, Inc. Secreted polypeptides with homology to xenopus cement gland proteins
AU8921598A (en) * 1997-08-29 1999-03-16 Human Genome Sciences, Inc. 29 human secreted proteins
AU1726199A (en) * 1997-12-31 1999-07-19 Chiron Corporation Metastatic cancer regulated gene
US5929033A (en) * 1998-02-10 1999-07-27 Incyte Pharmaceuticals, Inc. Extracellular mucous matrix glycoprotein
DE19817946A1 (de) * 1998-04-17 1999-10-21 Metagen Gesellschaft Fuer Genomforschung Mbh Menschliche Nukleinsäuresequenzen aus Uterus-Normalgewebe
US6262333B1 (en) * 1998-06-10 2001-07-17 Bayer Corporation Human genes and gene expression products
EP1108021A2 (en) * 1998-08-31 2001-06-20 Bayer Corporation Human genes differentially expressed in colorectal cancer
AU2387900A (en) * 1998-12-23 2000-07-12 Corixa Corporation Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
WO2001022920A2 (en) * 1999-09-29 2001-04-05 Human Genome Sciences, Inc. Colon and colon cancer associated polynucleotides and polypeptides
AU4592601A (en) * 2000-03-21 2001-10-03 Millennium Predictive Medicine Novel genes, compositions, kits, and method for identification, assessment, prevention, and therapy of ovarian cancer

Also Published As

Publication number Publication date
JP2007289196A (ja) 2007-11-08
WO2002029086A3 (en) 2002-10-03
WO2002029086A2 (en) 2002-04-11
US20060179496A1 (en) 2006-08-10
AU2001294943A1 (en) 2002-04-15
US20040110668A1 (en) 2004-06-10
EP1330543A2 (en) 2003-07-30
EP1330543A4 (en) 2006-03-29

Similar Documents

Publication Publication Date Title
JP2007289196A (ja) 癌組織でディファレンシャルに発現される核酸配列
US20020144298A1 (en) Novel human genes and gene expression products
US20020076735A1 (en) Diagnostic and therapeutic methods using molecules differentially expressed in cancer cells
JP2003518920A (ja) 新規なヒト遺伝子および遺伝子発現産物
US20080131889A1 (en) Novel human genes and gene expression products: II
EP1287162A2 (en) Gene expression profiling of inflammatory bowel disease
JP2004512029A (ja) ヒト遺伝子および遺伝子発現産物
JP2004502406A (ja) ヒト遺伝子およびヒト遺伝子発現産物
EP1108021A2 (en) Human genes differentially expressed in colorectal cancer
JP2011254830A (ja) 結腸癌に関するポリヌクレオチド
US20030082603A1 (en) Colon cancer marker
US20040146879A1 (en) Novel human genes and gene expression products
US20070231814A1 (en) DNA sequences isolated from human colonic epithelial cells
JP2004505637A (ja) ガン関連ｓｉｍ２遺伝子
CA2430794A1 (en) Human genes and gene expression products isolated from human prostate
US6677119B2 (en) Methods of detecting a colon cancer cell
EP1593687A2 (en) Human genes differentially expressed in colon cancer
WO2003008561A2 (en) Genes associated with benign prostatic hyperplasia
WO2002077162A2 (en) Gene (t23490) associated with benign prostatic hyperplasia

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20051031

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20060130

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20060207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060428

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060607

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20060831

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20060907

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20061129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061206

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20070206